Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethics Committees, Research | 2 | 2018 | 22 | 1.220 |
Why?
|
| Marijuana Abuse | 9 | 2019 | 251 | 1.020 |
Why?
|
| Biomedical Research | 2 | 2018 | 310 | 0.950 |
Why?
|
| Substance-Related Disorders | 12 | 2014 | 1242 | 0.890 |
Why?
|
| Alcoholism | 15 | 2011 | 1109 | 0.680 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2019 | 467 | 0.620 |
Why?
|
| Bipolar Disorder | 7 | 2000 | 307 | 0.580 |
Why?
|
| Acetylcysteine | 5 | 2019 | 296 | 0.500 |
Why?
|
| Smoking Cessation | 6 | 2018 | 1032 | 0.450 |
Why?
|
| Videotape Recording | 1 | 2013 | 43 | 0.450 |
Why?
|
| Research Subjects | 1 | 2013 | 45 | 0.440 |
Why?
|
| Patient Preference | 1 | 2013 | 57 | 0.430 |
Why?
|
| Cocaine-Related Disorders | 9 | 2014 | 504 | 0.430 |
Why?
|
| Informed Consent | 1 | 2013 | 127 | 0.410 |
Why?
|
| Cannabis | 5 | 2019 | 115 | 0.390 |
Why?
|
| Marijuana Smoking | 4 | 2019 | 108 | 0.350 |
Why?
|
| Adult | 41 | 2021 | 21379 | 0.330 |
Why?
|
| Stress Disorders, Post-Traumatic | 10 | 2006 | 1506 | 0.330 |
Why?
|
| Naltrexone | 2 | 2021 | 195 | 0.330 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2021 | 92 | 0.310 |
Why?
|
| Sertraline | 6 | 2006 | 62 | 0.310 |
Why?
|
| Research Design | 4 | 2018 | 729 | 0.290 |
Why?
|
| Narcotic Antagonists | 3 | 2021 | 184 | 0.290 |
Why?
|
| Mood Disorders | 2 | 2005 | 132 | 0.290 |
Why?
|
| Comorbidity | 16 | 2019 | 1425 | 0.280 |
Why?
|
| Cannabinoids | 2 | 2017 | 90 | 0.280 |
Why?
|
| Humans | 52 | 2021 | 68549 | 0.280 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 9 | 2010 | 151 | 0.270 |
Why?
|
| Depressive Disorder, Major | 1 | 2010 | 438 | 0.260 |
Why?
|
| Female | 40 | 2021 | 38021 | 0.250 |
Why?
|
| Opioid-Related Disorders | 4 | 2013 | 298 | 0.250 |
Why?
|
| Male | 38 | 2021 | 37283 | 0.250 |
Why?
|
| Carbamazepine | 3 | 2002 | 108 | 0.230 |
Why?
|
| Tobacco Use Disorder | 2 | 2019 | 432 | 0.230 |
Why?
|
| Double-Blind Method | 13 | 2021 | 1738 | 0.230 |
Why?
|
| Antidepressive Agents, Second-Generation | 5 | 2014 | 53 | 0.220 |
Why?
|
| Adolescent | 18 | 2021 | 8904 | 0.220 |
Why?
|
| Bupropion | 2 | 2021 | 63 | 0.210 |
Why?
|
| Naloxone | 2 | 2013 | 56 | 0.210 |
Why?
|
| Treatment Outcome | 19 | 2019 | 7028 | 0.210 |
Why?
|
| Smoking | 5 | 2019 | 1449 | 0.200 |
Why?
|
| Buprenorphine | 2 | 2013 | 67 | 0.200 |
Why?
|
| Stress, Psychological | 2 | 2016 | 824 | 0.190 |
Why?
|
| Nutrition Disorders | 1 | 2000 | 16 | 0.190 |
Why?
|
| Ambulatory Care | 5 | 2008 | 339 | 0.190 |
Why?
|
| Buspirone | 2 | 2015 | 36 | 0.180 |
Why?
|
| Middle Aged | 21 | 2021 | 21119 | 0.180 |
Why?
|
| Young Adult | 11 | 2021 | 5710 | 0.180 |
Why?
|
| Nausea | 1 | 2000 | 47 | 0.180 |
Why?
|
| Depression | 4 | 2019 | 942 | 0.170 |
Why?
|
| Methamphetamine | 1 | 2021 | 132 | 0.170 |
Why?
|
| Medication Adherence | 3 | 2021 | 335 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2019 | 435 | 0.160 |
Why?
|
| Crack Cocaine | 1 | 1998 | 20 | 0.150 |
Why?
|
| Human Experimentation | 1 | 2018 | 19 | 0.150 |
Why?
|
| Anxiety | 2 | 2016 | 422 | 0.150 |
Why?
|
| Academies and Institutes | 1 | 2018 | 31 | 0.150 |
Why?
|
| Health Facilities | 1 | 2018 | 36 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2000 | 331 | 0.150 |
Why?
|
| Personality Disorders | 1 | 1998 | 44 | 0.150 |
Why?
|
| Suicide | 2 | 2016 | 115 | 0.150 |
Why?
|
| North Carolina | 1 | 2018 | 224 | 0.150 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 1998 | 45 | 0.150 |
Why?
|
| Counseling | 4 | 2014 | 279 | 0.140 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 104 | 0.140 |
Why?
|
| Sex Factors | 6 | 2017 | 1265 | 0.140 |
Why?
|
| Universities | 1 | 2018 | 191 | 0.140 |
Why?
|
| Riboflavin | 1 | 2015 | 15 | 0.130 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2015 | 34 | 0.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2011 | 189 | 0.120 |
Why?
|
| Opiate Substitution Treatment | 2 | 2011 | 57 | 0.120 |
Why?
|
| Anticonvulsants | 3 | 2002 | 223 | 0.120 |
Why?
|
| Menthol | 1 | 2013 | 11 | 0.120 |
Why?
|
| Free Radical Scavengers | 3 | 2019 | 112 | 0.110 |
Why?
|
| Comprehension | 1 | 2013 | 71 | 0.110 |
Why?
|
| Health Literacy | 1 | 2013 | 62 | 0.110 |
Why?
|
| Pilot Projects | 4 | 2013 | 1341 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2011 | 782 | 0.110 |
Why?
|
| Prescription Drugs | 1 | 2013 | 71 | 0.100 |
Why?
|
| Lithium | 3 | 1999 | 76 | 0.100 |
Why?
|
| Valproic Acid | 3 | 1999 | 93 | 0.100 |
Why?
|
| Anti-Anxiety Agents | 2 | 2004 | 107 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2011 | 951 | 0.100 |
Why?
|
| Anxiety Disorders | 2 | 2004 | 426 | 0.090 |
Why?
|
| Methylphenidate | 1 | 2011 | 97 | 0.090 |
Why?
|
| Tobacco Products | 1 | 2013 | 234 | 0.090 |
Why?
|
| Behavior, Addictive | 2 | 2013 | 317 | 0.090 |
Why?
|
| Community Health Services | 1 | 2011 | 141 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 56 | 0.090 |
Why?
|
| Recurrence | 3 | 2008 | 948 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 648 | 0.090 |
Why?
|
| Psychotherapy, Group | 1 | 2010 | 55 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2021 | 411 | 0.090 |
Why?
|
| Nicotine | 2 | 2010 | 350 | 0.090 |
Why?
|
| Self Report | 3 | 2017 | 370 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 221 | 0.080 |
Why?
|
| Cyclohexanols | 2 | 2001 | 12 | 0.080 |
Why?
|
| Dronabinol | 2 | 2019 | 84 | 0.080 |
Why?
|
| Residential Treatment | 1 | 2008 | 24 | 0.080 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2008 | 71 | 0.080 |
Why?
|
| Remote Consultation | 1 | 2008 | 50 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2013 | 498 | 0.070 |
Why?
|
| Prevalence | 3 | 2019 | 1609 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 766 | 0.070 |
Why?
|
| Telephone | 1 | 2008 | 160 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2006 | 15 | 0.070 |
Why?
|
| Quantitative Trait Loci | 1 | 2006 | 35 | 0.070 |
Why?
|
| Age Factors | 3 | 2017 | 1860 | 0.070 |
Why?
|
| Genetic Linkage | 1 | 2006 | 90 | 0.070 |
Why?
|
| Self-Help Groups | 1 | 2005 | 38 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 2005 | 83 | 0.060 |
Why?
|
| Stochastic Processes | 1 | 2005 | 27 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 186 | 0.060 |
Why?
|
| United States | 4 | 2017 | 7338 | 0.060 |
Why?
|
| Defense Mechanisms | 1 | 2003 | 14 | 0.060 |
Why?
|
| Triazoles | 1 | 2004 | 43 | 0.060 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 2 | 2014 | 19 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 1140 | 0.050 |
Why?
|
| Neurobiology | 1 | 2001 | 9 | 0.050 |
Why?
|
| Patient Selection | 1 | 2005 | 592 | 0.050 |
Why?
|
| Substance Abuse Detection | 1 | 2001 | 66 | 0.050 |
Why?
|
| Paroxetine | 1 | 2001 | 28 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 929 | 0.050 |
Why?
|
| Emergency Treatment | 1 | 2001 | 52 | 0.050 |
Why?
|
| Biomarkers | 2 | 2017 | 1593 | 0.050 |
Why?
|
| Injections | 1 | 2021 | 119 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 120 | 0.050 |
Why?
|
| Hospitalization | 3 | 1995 | 977 | 0.050 |
Why?
|
| Age of Onset | 2 | 2005 | 188 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2000 | 122 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2001 | 135 | 0.040 |
Why?
|
| Antimanic Agents | 1 | 1999 | 21 | 0.040 |
Why?
|
| Marital Status | 2 | 2003 | 65 | 0.040 |
Why?
|
| Phobic Disorders | 1 | 2001 | 227 | 0.040 |
Why?
|
| Public Health | 1 | 2001 | 201 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 1999 | 130 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2001 | 383 | 0.040 |
Why?
|
| Medical Marijuana | 1 | 2018 | 21 | 0.040 |
Why?
|
| Sulpiride | 1 | 2017 | 20 | 0.040 |
Why?
|
| Tobacco Use | 1 | 2018 | 98 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 521 | 0.040 |
Why?
|
| Help-Seeking Behavior | 1 | 2017 | 13 | 0.040 |
Why?
|
| Psychotherapy | 1 | 1999 | 253 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1753 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2017 | 40 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2001 | 1329 | 0.030 |
Why?
|
| 1-Naphthylamine | 1 | 1995 | 11 | 0.030 |
Why?
|
| Motivation | 1 | 2019 | 561 | 0.030 |
Why?
|
| Aged | 5 | 2021 | 14842 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2001 | 702 | 0.030 |
Why?
|
| Mass Screening | 1 | 2001 | 838 | 0.030 |
Why?
|
| Patient Compliance | 2 | 2008 | 402 | 0.030 |
Why?
|
| Placebos | 2 | 2006 | 195 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2006 | 219 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 563 | 0.030 |
Why?
|
| Irritable Mood | 1 | 1994 | 15 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 621 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1465 | 0.030 |
Why?
|
| Fluoxetine | 1 | 1993 | 40 | 0.030 |
Why?
|
| Educational Status | 1 | 1994 | 273 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2014 | 159 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2077 | 0.030 |
Why?
|
| Osmosis | 1 | 2011 | 38 | 0.030 |
Why?
|
| Self Administration | 1 | 2013 | 419 | 0.020 |
Why?
|
| Methadone | 1 | 2011 | 32 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2011 | 113 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2017 | 659 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2008 | 3256 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2265 | 0.020 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2001 | 42 | 0.020 |
Why?
|
| Aftercare | 1 | 2008 | 114 | 0.020 |
Why?
|
| Lod Score | 1 | 2006 | 14 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2006 | 16 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2006 | 56 | 0.020 |
Why?
|
| Pedigree | 1 | 2006 | 159 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1851 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2006 | 197 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2006 | 207 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 2006 | 805 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 652 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2006 | 257 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2008 | 294 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 306 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2005 | 84 | 0.020 |
Why?
|
| Genotype | 1 | 2006 | 785 | 0.010 |
Why?
|
| Drug Interactions | 2 | 1995 | 289 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 946 | 0.010 |
Why?
|
| Piperazines | 1 | 2004 | 206 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2003 | 117 | 0.010 |
Why?
|
| Crime Victims | 1 | 2005 | 286 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 714 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 1040 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 955 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 567 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1999 | 37 | 0.010 |
Why?
|
| Transaminases | 1 | 1999 | 21 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1999 | 114 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 4655 | 0.010 |
Why?
|
| Child Abuse | 1 | 1998 | 186 | 0.010 |
Why?
|
| Absorption | 1 | 1995 | 49 | 0.010 |
Why?
|
| Liver | 1 | 1999 | 1118 | 0.010 |
Why?
|
| Acute Disease | 1 | 1995 | 658 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 1993 | 107 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1995 | 848 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1993 | 1745 | 0.010 |
Why?
|
| Rats | 1 | 1995 | 5300 | 0.000 |
Why?
|
| Child | 1 | 1998 | 6401 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1998 | 7268 | 0.000 |
Why?
|
| Animals | 1 | 1995 | 20880 | 0.000 |
Why?
|